FDC Limited Stock Price Today (NSE: FDC)
Fundamental Score
FDC Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
FDC Limited share price today is ₹350.20, up +0.14% on NSE/BSE as of 16 September 2026. FDC Limited (FDC) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹5.70K (Cr). The 52-week high for FDC share price is ₹527.80 and the 52-week low is ₹312.95. At a P/E ratio of 19.48x, FDC is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.81% and a debt-to-equity ratio of 0.00.
FDC Limited Share Price Chart — NSE/BSE Historical Performance
FDC Limited share price chart: -1.68% return over the past month. 52-week high ₹527.80, 52-week low ₹312.95.
FDC Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹350.70 | ₹358.80 | ₹340.05 | ₹350.20 | 2.39L (Cr) | |
| ₹340.00 | ₹354.85 | ₹339.75 | ₹349.70 | 4.70L (Cr) | |
| ₹344.00 | ₹344.80 | ₹339.00 | ₹341.45 | 1.36L (Cr) | |
| ₹356.75 | ₹356.75 | ₹344.55 | ₹345.35 | 1.15L (Cr) | |
| ₹345.85 | ₹356.75 | ₹342.40 | ₹354.30 | 2.20L (Cr) | |
| ₹343.00 | ₹347.50 | ₹341.95 | ₹345.95 | 62.73K (Cr) | |
| ₹345.55 | ₹345.55 | ₹338.60 | ₹342.15 | 89.17K (Cr) | |
| ₹343.00 | ₹351.80 | ₹341.55 | ₹342.80 | 1.20L (Cr) | |
| ₹342.00 | ₹344.05 | ₹339.05 | ₹341.60 | 92.29K (Cr) | |
| ₹334.25 | ₹344.60 | ₹328.80 | ₹340.60 | 1.59L (Cr) |
FDC Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹338.40 | ₹358.80 | ₹328.80 | ₹350.20 | +3.49% | |
| ₹409.80 | ₹425.05 | ₹329.50 | ₹337.20 | -17.72% | |
| ₹423.00 | ₹442.00 | ₹397.05 | ₹409.80 | -3.12% | |
| ₹408.00 | ₹432.00 | ₹373.25 | ₹423.85 | +3.88% | |
| ₹364.50 | ₹439.45 | ₹353.80 | ₹405.00 | +11.11% | |
| ₹325.50 | ₹376.30 | ₹320.50 | ₹364.45 | +11.97% | |
| ₹350.65 | ₹385.00 | ₹312.95 | ₹321.10 | -8.43% | |
| ₹376.90 | ₹399.50 | ₹350.35 | ₹356.65 | -5.37% | |
| ₹422.00 | ₹422.70 | ₹358.75 | ₹377.75 | -10.49% | |
| ₹414.45 | ₹433.45 | ₹403.55 | ₹423.10 | +2.09% | |
| ₹463.85 | ₹473.60 | ₹405.00 | ₹414.40 | -10.66% | |
| ₹446.20 | ₹476.40 | ₹429.15 | ₹460.65 | +3.24% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
FDC Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
FDC Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of FDC across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (15.47%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 19.48 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (76.13x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.01)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹433.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Weak Earnings Growth (-0.49% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-1.36% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 8.69%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
FDC Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare FDC Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
FDC LimitedFDC Limited...Selected✓ FDC • 531599 | 60.4/100 | ₹350.20₹350 | ₹5701.26₹5701.26 | 19.48Average 19.5 Average | 11.81%Average 11.81% Average | 15.47%Good 15.47% Good | 0.00Excellent 0.0 Excellent | -1.36%Poor -1.36% Poor | 10.24%Good 10.24% Good | 1.18% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.00₹1861 | ₹446509.73₹446509.73 | 36.92Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9393.50₹9394 | ₹248927.75₹248927.75 | 85.23Average 85.2 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1117.80₹1118 | ₹111556.44₹111556.44 | 24.91Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1374.50₹1375 | ₹111038.98₹111038.98 | 32.93Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1944.00₹1944 | ₹105024.60₹105024.60 | 95.95Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.20₹1666 | ₹95873.15₹95873.15 | 26.03Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.00₹1141 | ₹95273.50₹95273.50 | 29.49Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2074.00₹2074 | ₹94833.65₹94833.65 | 17.14Average 17.1 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2246.00₹2246 | ₹92759.80₹92759.80 | 45.38Average 45.4 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446509.73 Cr
- Divi's Laboratories Limited share price248927.75 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price111556.44 Cr
- Cipla Limited share price111038.98 Cr
FDC Limited PE Ratio History
Historical price-to-earnings ratio for FDC — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹16.39 | ₹423.10 | 25.8x |
| FY 2024 | ₹1858.00 | ₹499.45 | 0.3x |
| FY 2023 | ₹11.67 | ₹396.45 | 34x |
| FY 2022 | ₹12.82 | ₹270.85 | 21.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
FDC Limited Dividend History
Annual cash dividends paid by FDC — dividend yield 1.18%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹81.13 Cr |
| FY 2024 | ₹0.15 Cr |
| FY 2023 | ₹0.18 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
FDC Limited Quarterly Performance
Latest quarterly metrics for FDC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
2.97%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.18%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.24%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-1.36%
Compounded annual net profit growth over 5 years
FDC Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for FDC — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
FDC Limited Financial Statements
Annual income statement, balance sheet and cash flow for FDC Limited (FDC) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for FDC Limited
About FDC (FDC Limited)
FDC Ltd is a pioneering pharmaceutical company deeply rooted in the Indian subcontinent, with expanding influence across international markets. It's an organisation driven by innov...ation, continually researching and developing novel therapeutic solutions. Their core strength lies in crafting accessible, high-quality medications that address a diverse range of health needs. FDC is synonymous with robust manufacturing practices, ensuring adherence to the most stringent global regulatory standards. They are deeply committed to improving patient outcomes. FDC invests heavily in cutting-edge technology and advanced research facilities to stay at the forefront of pharmaceutical innovation. They have forged a reputation for reliability and efficacy among healthcare professionals and patients alike. The company's product portfolio is remarkably diverse, spanning across essential therapeutic categories. From tackling infectious diseases with potent anti-infectives to providing relief for digestive ailments and enhancing eye health with specialised ophthalmic treatments, FDC offers a comprehensive range of solutions. They are also significant players in addressing chronic conditions, providing effective cardiovascular and anti-diabetic therapies. With a keen eye on evolving health challenges, FDC develops innovative respiratory care products, supports women's health through gynaecological solutions, and offers specialised dermatological treatments. FDC also manufactures vital supplements and trusted analgesics to further support overall well-being and quality of life. FDC's commitment extends beyond manufacturing and distribution. They have cultivated strong relationships with healthcare providers, researchers, and regulatory bodies to foster collaboration and knowledge sharing. FDC dedicates resources to patient education programs, empowering individuals to make informed decisions about their health. Their dedication to ethical practices, environmental sustainability, and social responsibility are cornerstones of their business philosophy. FDC strives to be a trusted partner in global healthcare, dedicated to enhancing lives and providing accessible, effective pharmaceutical solutions to a global patient population.
Company Details
Key Leadership
FDC Share Price: Frequently Asked Questions
What is the current share price of FDC Limited?
FDC Limited (FDC) trades at ₹350.20 on NSE and BSE. Market cap ₹5.70K (Cr). Educational data only.
What is the P/E ratio of FDC Limited?
FDC Limited has a P/E of 19.48x vs industry average 34.89x.
What is the Bull Run score for FDC Limited?
FDC Limited has a Bull Run score of 60.4/100 based on 25+ financial parameters.
Does FDC Limited pay dividends?
FDC Limited has a dividend yield of 1.18%. Past dividends don't guarantee future payments.
What is the ROE of FDC Limited?
FDC Limited has ROE of 11.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of FDC Limited?
FDC Limited has debt-to-equity of 0.00.
Is FDC Limited a good investment?
Bull Run gives FDC Limited a score of 60.4/100. This is not investment advice — consult a SEBI-registered advisor.